| Autor: |
Simona Costanzo, Augusto Di Castelnuovo, Teresa Panzera, Amalia De Curtis, Stefania Falciglia, Mariarosaria Persichillo, Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, the Moli-sani Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
International Journal of Public Health, Vol 69 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1661-8564 |
| DOI: |
10.3389/ijph.2024.1607682 |
| Popis: |
ObjectivesWe evaluated the impact of polypharmacy on the health of community-dwelling older adults.MethodsWe prospectively analyzed 5,631 individuals from the Moli-sani study (51% men, aged ≥65 years, recruitment 2005–2010, follow-up 2005–2020). Exposure was categorized as chronic polypharmacy therapy (C-PT; ≥5 therapeutic groups and >2 defined daily doses (DDDs)) or non-chronic polypharmacy therapy (NC-PT; polypharmacy but ≤2 DDDs). Hospitalization and mortality were the main outcomes. The mediating role of potentially inappropriate prescriptions (PIP) was examined.ResultsCompared to individuals not on polypharmacy, those in NC-PT and C-PT had higher hazards of mortality [21% (95% CI 7%–37%) and 30% (16%–46%), respectively] and hospitalization [39% (28%–51%) and 61% (49%–75%), respectively]. Similar results were found for cardiovascular outcomes. PIP mediated the association between polypharmacy and outcomes, with mediation effects ranging from 13.6% for mortality to 6.0% for hospitalization. Older adults without multimorbidity experienced the same harm from multiple medications as those with multimorbidity.ConclusionPolypharmacy is associated with a higher hazard of mortality and hospitalization, with PIP playing an important role. Addressing “medication without harm” requires assessing the appropriateness of drug prescriptions and monitoring for adverse effects. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
